EC Number   |
Application |
Reference |
|---|
    3.2.1.22 | analysis |
comparison of glycolytic and chitinolytic enzyme activities between desert and oasis flies of Phlebotomus papatasi to evaluate potential differences in susceptibility to infection with Leishmania major |
679943 |
| 3.2.1.22 | analysis |
determinantion of alpha-galactosidase A activity in samples from patients with Fabry disease and healthy controls. Average enzyme activity in dried blood spot samples prepared using EDTA tubes is higher compared to those spotted directly irrespective of disease status |
697401 |
| 3.2.1.22 | biotechnology |
Concavalin A-alpha-galactosidase complex entrapped in calcium alginate and crosslinked Concavalin A-alpha-galactosidase complex entrapped calcium alginate retain 74 and 61% activity, respectively. Crosslinked Concavalin A-alpha-galactosidase entrapped complex exhibit enhanced thermostability and show 62% of activity (38%) after 360 min at 65°C. Entrapped crosslinked Concavalin A-alpha-galactosidase complex preparation is superior in the continuous hydrolysis of oligosaccharides in soymilk by batch processes compared to the other entrapped preparations |
715801 |
| 3.2.1.22 | degradation |
enzyme completely hydrolyzes raffinose and stachyose present in soybeans and kidney beans at 50°C within 60 min |
-, 742095 |
| 3.2.1.22 | medicine |
determinantion of alpha-galactosidase A activity in samples from patients with Fabry disease and healthy controls. Average enzyme activity in dried blood spot samples prepared using EDTA tubes is higher compared to those spotted directly irrespective of disease status |
697401 |
| 3.2.1.22 | medicine |
enzyme activity is detected in unstimulated whole saliva and mainly due to isoform A activity. Activity is higher in unclarified samples than in clarified ones and shows wide daily variations. Activity in whole salivea is significantly higher than in glandular saliva. There is no difference in activity according to gender, blood type, and secretor status |
695927 |
| 3.2.1.22 | medicine |
Fabry disease is a lysosomal storage disorder caused by deficient lysosomal alpha-galactosidase A activity. Rapid degradation of mutant R301Q is observed in TgM/KO mouse fibroblasts treated with brefeldin A, and the amount of R301Q enzyme markedly increases by pretreatment with 1-deoxygalactonojirimycin starting 12 h prior to addition of brefeldin A. The enhancement of alpha-galactosidase A activity and its protein level by 1-deoxygalactonojirimycin-treatment is selectively observed in brefeldin A-treated COS-7 cells expressing R301Q |
696400 |
| 3.2.1.22 | medicine |
Fabry disease is a X-linked inborn error of glycolipid metabolism caused by deficiency of the lysosomal enzyme alpha-galactosidase A. An improved method of production of recombinant alpha-galactosidase A for use in humans is needed in order to develop new approaches for enzyme therapy. Purified recombinant enzyme is taken up by fibroblasts derived from fabry disease patients and normal enzyme levels can be restored under theses conditions |
657237 |
| 3.2.1.22 | medicine |
Fabry disease is an X-linked genetic disorder resulting from a deficiency of alpha-galactosidase activity. Correlation of structural changes and clinical and biochemical phenotypes is demonstrated. Structural investigation is useful for elucidating the bases of Fabry disease and clinical treatment |
665127 |
| 3.2.1.22 | medicine |
in male patients with Fabry disease, an X-linked disorder of glycosphingolipid metabolism caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, treatment with agalsidase alfa, i.e. alpha-galactosidase A produced by gene activation in a human cell line, does not affect proteinuria. Agalsidase alfa may stabilize kidney function |
698501 |
